VCELVericel Corporation
$40.12+27% 1Y
$40.12
$29.3452 weeks$47.81
The financials
Vericel Corporation by the numbers
Vericel Corporation (VCEL) reported revenue of $77M in Q2 2026 (quarter ended Jun 30, 2026), up 22% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $2.2M (2.8% of revenue). For the full year FY2025, revenue was $276M (+16% year on year) and net income $17M. Its largest product in Q2 2026 was MACI Implants And Kits at $66M, 86% of the disclosed total, well ahead of Epicel at 14%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $77M | $63M | +22% |
| Gross profit | $56M | $47M | +21% |
| Operating income | $434K | −$2.0M | to a profit |
| Net income | $2.2M | −$553K | to a profit |
| Diluted EPS | $0.04 | −$0.01 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| MACI Implants And Kits | $66M | 86% |
| Epicel | $10M | 14% |
| Biopsy Kits | $614K | 0.8% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $76.5M (+13%)
MACI Implants And Kits grew +23% year on yearBiopsy Kits -4.4% year on year
Segment Latestquarter on quarteryear on year
- MACI Implants And Kits$65.5M$65.5Mquarter on quarter +16%year on year +23%+16%+23%
- Epicel$10.4M$10.4Mquarter on quarter -4.4%year on year +21%-4.4%+21%
- Biopsy Kits$614.0K$614.0Kquarter on quarter +1.3%year on year -4.4%+1.3%-4.4%
On our screens:Most shorted stocks